Abivax

Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.

Filings

5 filings

All Threshold crossing47 Inside information40 Voting rights and capital19 Quarterly financial information5 Earnings release5 Half-year financial report4 Universal registration document2 AGM documents1

22/05/2026
Déclaration de la personne responable du rapport financier intermédiaire du 1er trimestre
Quarterly financial informationFrench
22/05/2026
Etats financiers consolidés condensés intermédiaires (non audités) au 31 mars 2026
Quarterly financial informationFrench
15/12/2025
Déclaration de la personne responsable du rapport financier intermédiaire
Quarterly financial informationFrench
02/06/2025
Déclaration de la personne responsable du rapport financier intermédiaire
Quarterly financial informationFrench
02/06/2025
Etats financiers consolidés condensés intermédiaires (non audités) au 31 mars 2025
Quarterly financial informationFrench

About

ISIN: FR0012333284
Ticker: ABVX
LEI: 969500D8TMNB184OJU95
Sector: Health care
Country of registration: FR
Last filing: 30/07/2026, 22:05

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive